Histone methyltransferases: A new class of therapeutic targets in cancer treatment?;Histone méthyltransférases: Une nouvelle classe de cibles therapeutiques dans le traitement du cancer?

Medecine/Sciences

Volumn 27, Issue 8-9, 2011, Pages 725-732

  Chaib, Hassiba ^a,b   Prébet, Thomas ^a,b   Vey, Norbert ^a,b   Collette, Yves ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HISTONE; HISTONE DEACETYLASE INHIBITOR; HISTONE LYSINE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE; METHYLTRANSFERASE; PRMT1 PROTEIN, HUMAN; PROTEIN ARGININE METHYLTRANSFERASE; REPRESSOR PROTEIN; SUV39H1 PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LEUKEMIA; METABOLISM; METHYLATION; MOLECULARLY TARGETED THERAPY; MOUSE; PHYSIOLOGY; PROTEIN PROCESSING; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; LEUKEMIA; METHYLATION; METHYLTRANSFERASES; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-ARGININE N-METHYLTRANSFERASES; REPRESSOR PROTEINS;

EID: 80052942653     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2011278014     Document Type: Article

References (30)

1. Ray-Gallet D, Gérard A, Polo S, Almouzni G. Variations sur le thème du «code histone». Med Sci (Paris) 2005;21:384-9. (Pubitemid 40544069)
2. Kouzarides T. Chromatin modifications and their function. Ceil 2007;128:693-705. (Pubitemid 46273577)
3. Mottet D, Castronovo V. Les histone désacétylases. Nouvelles cibles pour les thérapies anti-cancéreuses. Med Sci (Paris) 2008;24:742-6.
4. Sowa Y. Development of HDAC inhibitors. Can To Kagaku Ryoho 2010;37:1665-8.
5. Albert M, Kelin K. Histone methyltransferases in cancer. Sent Cell Dev Biol 2010;21:209-20.
6. Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev 2002;12:198-209. (Pubitemid 34219493)
7. Schneider R, Bannister AJ, Kouzarides T. Unsafe SET: histone lysine methyltransferases and cancer. Trends Biochem Sci 2002;27:396-402. (Pubitemid 34874749)
8. Peters AH, O'Carroll D, Scherthan H, et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 2001;107:323-37. (Pubitemid 33049976)
9. Czvitkovich S, Sauer S, Peters AH, et al. Over-expression of the SUV39H1 histone methyltransferase induces altered proliferation and differentiation in transgenic mice. Mech Dev 2001;107:141-53. (Pubitemid 32755812)
10. Nielsen SJ, Schneider R, Bauer UM, et al. Rb targets histone H3 methylation and HP1 to promoters. Nature 2001;412:561-5. (Pubitemid 32743837)
11. Owa T, Yoshino H, Yoshimatsu K, Nagasu T. Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem 2001;8:1487-503. (Pubitemid 32894011)
12. Cattaneo F, Nucifora G. EVI1 recruits the histone methyltransferase SUV39H1 for transcription repression. J Cell Btochem 2008;105:344-52.
13. Carbone R, Botrugno OA, Ronzoni S, et al. Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein. Mot Cell Biol 2006;26:1288-96. (Pubitemid 43202556)
14. Goyama S, Nitta E, Yoshino T, et al. EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization. Leukemia 2010;24:81-8.
15. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007;7:823-33. (Pubitemid 350006257)
16. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001;20:5695-707. (Pubitemid 32928107)
17. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 2003;17:2298-307. (Pubitemid 37128644)
18. Okada Y, Feng Q, Lin Y, et al. hDOTIL links histone methylation to leukemogenesis. Cell 2005;121:167-78. (Pubitemid 40546386)
19. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are dis-associated in senescent cells. Genes Dev 2007;21:525-30. (Pubitemid 46409467)
20. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
21. Bedford MT, Richard S. Arginine methylation an emerging regulator of protein function. Mol Cell 2005;18:263-72. (Pubitemid 41350532)
22. Cheung N, Chan LC, Thompson A, et al. Protein arginine- methyltransferasedependent oncogenesis. Nat Cell Biol 2007;9:1208-15.
23. Majumder S, Liu Y, Ford OH, et al. Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability. The Prostate 2006;66:1292-301. (Pubitemid 44384306)
24. Greiner D, Bonaldi T, Eskeland R, et al. Identification of a specific inhibitor of the histone methyltransferase SU (VAR) 3-9. Nat Chem Biol 2005;1:143-5.
25. Cook KM, Hilton ST, Mecinovic J, et al. Epidithiodiketapiperazines block the interaction between hypoxia-inducible factor-lalpha (HIF-lalpho) and p300 by a zinc ejection mechanism. J Biol Chem 2009;284:26831-8.
26. Isham CR, Tibodeau JD, Jin W, et al. Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood 2007;109:2579-88. (Pubitemid 46425905)
27. Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of Polycombrepressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007;21:1050-63. (Pubitemid 46686474)
28. Kubicek S, O'Sullivan RJ, August EM, et al. Reversal of H3K9me2 by a smallmolecule inhibitor for the G9a histone methyltransferase. Mol Cell 2007;25:473-81. (Pubitemid 46206139)
29. Cheng D, Yadav N, King RW, et al. Small molecule regulators of protein arginine methyltransferases. J Biol Chem 2004;279:23892-9. (Pubitemid 38725246)
30. Spannhoff A, Machmur R, Heinke R, et al. A novel arginine methyltransferase inhibitor with cellular activity. Bioorg Med Chem Lett 2007;17:4150-3. (Pubitemid 47021405)